Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Basking Ridge, New JerseyAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT06546150RecruitingPhase 1
Cell therapy for KRAS G12V mutated advanced solid tumors
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
Zhengzhou, HenanAges 18–75 - NCT07297667RecruitingPhase 1
CAR T-cell therapy for certain advanced solid tumors
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Calgary, AlbertaAges 15 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06956248Recruiting
Access to new treatments for advanced solid tumors
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
SingaporeAges 21–99 - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT07321015RecruitingPhase 2
Fluzoparib after platinum for advanced triple-negative breast cancer
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
TianjinAges 18–75 - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07416994RecruitingPhase 3
Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT05677490RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced stomach or esophagus cancer
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
Birmingham, AlabamaAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.